Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is reporting third quarter financial results on Thursday 5th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, AGIO is expected to report 3Q20 loss of $ 1.38 per share from revenue of $ 38.02 million.
For the full year, analysts anticipate top line of $ 204.84 million, while looking forward to loss of $ 4.72 per share bottom line.
Previous Quarter Performance
Agios Pharmaceuticals, Inc. posted loss for the second quarter of $ 1.31 per share, from the revenue of $ 37.35 million. The quarterly revenues swell 42.45 percent compared with the same quarter last year. Street analysts expected Agios Pharmaceuticals, Inc. to report loss of $ 1.37 per share on revenue of $ 37.71 million for the second quarter. The bottom line results beat street analysts by $ 0.06 or 4.38 percent, at the same time, top line results fell short of analysts by $ 0.36 million or 0.95 percent.
Stock Performance
Shares of Agios Pharmaceuticals, Inc. traded up $ 0.07 or 0.17 percent on Wednesday, reaching $ 41.52 with volume of 1.13 million shares. Agios Pharmaceuticals, Inc. has traded high as $ 44.14 and has cracked $ 40.25 on the downward trend
The closing price of $ 41.52, representing a 49.26 % increase from the 52 week low of $ 27.77 and a 26.96 % decrease over the 52 week high of $ 56.75.
The company has a market capital of $ 2.87 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 19th October 2020, maintained by Needham & Company LLC at Buy rating, with $ 69.00 target price.
- On 19th October 2020, maintained by Canaccord Genuity at Buy rating, with $ 70.00 target price.
- On 19th October 2020, maintained by SVB Leerink at Outperform rating, with $ 67.00 target price.
- On 19th October 2020, maintained by Piper Sandler at Overweight rating, with $ 73.00 target price.
Conference Call
Agios Pharmaceuticals, Inc. will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.agios.com
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors.
